New York-based Turing Pharmaceutivals, a privately held biopharmaceutical company, has named Eliseo Oreste Salinas as President of R&D.
Dr Salinas has played a leadership role in numerous programmes for a range of diseases and disorders, with a concentration on central nervous system conditions. He joins Turing as the company prepares to begin clinical trials for several of its drugs, including an innovative intranasal formulation for ketamine to treat severe depression.
Dr Salinas comes to Turing from Relmada Therapeutics, a New York-based clinical stage drug company focused primarily on pain management, where he was President and Chief Scientific Officer as well as Head of R&D. Prior to that he was Executive Vice President and Director of R&D for Newark, CA-based Stem Cells.
He has also held senior medical and science positions at Elan Pharmaceuticals, Adolor and Shire Pharmaceuticals, where he was Chief Scientific Officer. Earlier in his career, he led Wyeth’s worldwide research for central nervous system treatments.
